2.15 (-%)
As of Nov 21, 2024
Source:
Maia Biotechnology, Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO, our lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity.
| Country | United States |
| Headquarters | chicago, illinois |
| Phone Number | (312) 416-8592 |
| Industry | manufacturing |
| CEO | Vlad Vitoc |
| Website | www.maiabiotech.com |